WallStreetZen

NASDAQ: ATRC
AtriCure Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for ATRC

Based on 5 analysts offering 12 month price targets for AtriCure Inc.
Min Forecast
$65.00-9.41%
Avg Forecast
$91.20+27.11%
Max Forecast
$120.00+67.25%

Should I buy or sell ATRC stock?

Based on 6 analysts offering ratings for AtriCure Inc.
Buy
Strong Buy
2 analysts 33.33%
Buy
3 analysts 50%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

ATRC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDate
Canaccord Genuity
Top 34%
67
Strong BuyMaintains$120.00+67.25%2021-08-05
Oppenheimer
Bottom 4%
4
HoldDowngradesN/AN/A2021-08-05
SVB Leerink
Top 20%
81
BuyMaintains$100.00+39.37%2021-08-05
Needham
Top 7%
94
BuyMaintains$90.00+25.44%2021-08-05
JP Morgan
Top 27%
74
Strong BuyMaintains$81.00+12.89%2021-05-14
Anonymous
SVB Leerink
BuyMaintains$65.00-9.41%2020-12-14

1 of 1

Forecast return on equity

Is ATRC forecast to generate an efficient return?
Company
-7.03%
Industry
18.2%
Market
1,975.18%
ATRC's Return on Equity is forecast to be low in 3 years (-7.03%); analysts are not confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is ATRC forecast to generate an efficient return on assets?
Company
-3.86%
Industry
11.22%
Market
951.37%
ATRC is forecast to generate lower Return on Assets (-3.86%) than the US Medical Instruments & Supplies industry average (11.22%)
Forecast

ATRC earnings per share forecast

What is ATRC's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$1.23-3.91%
Avg 2 year Forecast
-$1.02-20.31%
Avg 3 year Forecast
-$0.59-53.91%

ATRC revenue forecast

What is ATRC's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$273.4M+12.47%
Avg 2 year Forecast
$324.8M+33.61%
Avg 3 year Forecast
$376.4M+54.8%
ATRC's revenue is forecast to grow at a rate of 15.6% per year, which is not exceptional
Forecast

ATRC revenue growth forecast

How is ATRC forecast to perform vs Medical Instruments & Supplies companies and vs the US market?
Company
15.6%
Industry
7.44%
Market
14.66%
ATRC's revenues are forecast to grow faster (15.6% per year) than the US Medical Instruments & Supplies industry average (7.44%)
Forecast
ATRC's revenues are forecast to grow faster (15.6% per year) than the US market average (14.66%)
Forecast

AtriCure Stock Forecast FAQ

Is AtriCure Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: ATRC) stock is to Buy ATRC stock.

Out of 6 analysts, 2 (33.33%) are recommending ATRC as a Strong Buy, 3 (50%) are recommending ATRC as a Buy, 1 (16.67%) are recommending ATRC as a Hold, 0 (0%) are recommending ATRC as a Sell, and 0 (0%) are recommending ATRC as a Strong Sell.

What is ATRC's earnings growth forecast for 2021-2023?

(NASDAQ: ATRC) AtriCure's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of 30.14%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 22.98%.

AtriCure's earnings in 2021 is -$56,679,000.On average, 2 Wall Street analysts forecast ATRC's earnings for 2021 to be $-56,435,412, with the lowest ATRC earnings forecast at $-57,353,061, and the highest ATRC earnings forecast at $-55,058,939. On average, 2 Wall Street analysts forecast ATRC's earnings for 2022 to be $-46,800,098, with the lowest ATRC earnings forecast at $-51,847,167, and the highest ATRC earnings forecast at $-41,753,029.

In 2023, ATRC is forecast to generate $-27,070,645 in earnings, with the lowest earnings forecast at $-32,576,539 and the highest earnings forecast at $-21,564,751.

What is ATRC's revenue growth forecast for 2021-2023?

(NASDAQ: ATRC) AtriCure's forecast annual revenue growth rate of 15.6% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 7.44%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 14.66%.

AtriCure's revenue in 2021 is $243,133,000.On average, 5 Wall Street analysts forecast ATRC's revenue for 2021 to be $12,546,280,384, with the lowest ATRC revenue forecast at $12,502,967,353, and the highest ATRC revenue forecast at $12,617,673,475. On average, 5 Wall Street analysts forecast ATRC's revenue for 2022 to be $14,904,638,263, with the lowest ATRC revenue forecast at $14,183,182,635, and the highest ATRC revenue forecast at $15,609,209,150.

In 2023, ATRC is forecast to generate $17,268,593,800 in revenue, with the lowest revenue forecast at $16,990,270,865 and the highest revenue forecast at $17,508,742,538.

What is ATRC's forecast return on assets (ROA) for 2021-2023?

(NASDAQ: ATRC) forecast ROA is -3.86%, which is lower than the forecast US Medical Instruments & Supplies industry average of 11.22%.

What is ATRC's Price Target?

According to 5 Wall Street analysts that have issued a 1 year ATRC price target, the average ATRC price target is $91.20, with the highest ATRC stock price forecast at $120.00 and the lowest ATRC stock price forecast at $65.00.

On average, Wall Street analysts predict that AtriCure's share price could stay at $91.20 by Aug 5, 2022. The average AtriCure stock price prediction forecasts a potential downside of N/A from the current ATRC share price of $71.75.

What is ATRC's Earnings Per Share (EPS) forecast for 2021-2023?

(NASDAQ: ATRC) AtriCure's current Earnings Per Share (EPS) is -$1.28. On average, analysts forecast that ATRC's EPS will be $-1.23 for 2021, with the lowest EPS forecast at $-1.25, and the highest EPS forecast at $-1.20. On average, analysts forecast that ATRC's EPS will be $-1.02 for 2022, with the lowest EPS forecast at $-1.13, and the highest EPS forecast at $-0.91. In 2023, ATRC's EPS is forecast to hit $-0.59 (min: $-0.71, max: $-0.47).

What is ATRC's forecast return on equity (ROE) for 2021-2023?

(NASDAQ: ATRC) forecast ROE is -7.03%, which is considered weak.
©2021 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending Stocks
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.